Back to News
Apr 22, 2026 4:00 PM

Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges

Inhibrx Biosciences Inc. (NASDAQ:INBX) is attracting interest from major drugmakers for its experimental cancer therapy INBRX-106, which could be valued at over $8 billion.

• Inhibrx Biosciences stock is challenging resistance. Why did INBX hit a new high?

The cancer-focused biotech is evaluating a potential joint spin-off of INBRX-106 alongside another early-stage oncology asset.

Reuters on Wednesday reported that if clinical trials are successful, the combined value of the two therapies could exceed $9 billion.

INBRX-106 Gains Attention For Keytruda Combination Potential

Interest has centered on INBRX-106, which is being tested both as a standalone therapy and in combination with Merck & Co. Inc.’s (NYSE:MRK) blockbuster immunotherapy, Keytruda (pembrolizumab).

The company plans to announce interim objective response rate data from the randomized Phase 2/3 trial in head and neck squamous cell carcinoma in combination with Keytruda in the second quarter of 2026, and progression-free survival data in the fourth quarter of 2026.

In March, Merck agreed to acquire Terns Pharmaceuticals Inc. (NASDAQ:TERN), as the U.S. drugmaker accelerates efforts to offset ...